Thymosin Alpha-1 Research Overview (also known as TA1, Thymalfasin, Zadaxin)

By , Founder of RUO Codes · Last updated

At a glance

Thymosin alpha-1 is a 28-amino-acid peptide first isolated from bovine thymus preparations. Its synthetic form is known as thymalfasin or Zadaxin. The page reviews immune-modulation and recovery research, alongside its international clinical history in hepatitis and adjunct cancer immunotherapy, distinguishing it from other short thymic peptides.

"

What Is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally occurring in thymosin fraction 5 (TF5), first isolated from bovine thymus by Allan Goldstein in the 1970s. The synthetic version — Thymalfasin (Zadaxin) — is approved in over 35 countries for hepatitis B, hepatitis C (with interferon), and as an adjunct in cancer immunotherapy. It is one of the most extensively studied immunomodulatory peptides with clinical approval.

Quick Reference

Member reference tables summarize the compound's research parameters.

Sign in to view this section

Mechanism of Action

Tα1 exerts its effects primarily on dendritic cells and T-cells. It promotes dendritic cell maturation and their production of IL-12, IFN-γ, and Type I interferons — cytokines critical for antiviral and antitumor immunity. It increases CD8+ cytotoxic T-cell activity and natural killer cell function, while reducing immunosuppressive regulatory T-cell activity in tumor microenvironments. It activates Toll-like receptor signaling through TLR2 and TLR9, linking it to innate immune pattern recognition.

Clinical Evidence

Multiple RCTs have demonstrated sustained virological response rates significantly higher than placebo in chronic hepatitis B, particularly when combined with interferon. Similar data exist for hepatitis C combination therapy. Cancer immunotherapy studies have shown improved tumor responses in melanoma, lung, and hepatocellular carcinoma. COVID-19 pandemic data demonstrated Tα1's benefit in severe COVID-19, with clinical trials in China documenting significantly reduced mortality in critical patients.

Research Indications

Immunity
Preliminary Data

Primary Immunodeficiencies

FDA orphan drug designation for DiGeorge syndrome with documented restoration of T-cell function and immune competence.

Vaccine Response Enhancement

Enhances immunogenicity in elderly and immunocompromised patients with improved antibody responses.

HIV/AIDS Immune Support

Restores CD4+ T-cell counts and reduces opportunistic infections with sustained immunological improvement.

Inflammation
Preliminary Data

Cytokine Storm Mitigation

Reduces pro-inflammatory cytokines by 40-60% while maintaining balanced immune responses.

Chronic Inflammatory Conditions

Modulates inflammatory responses in hepatitis, pancreatitis, and autoimmune conditions.

Recovery
Supported Research

Post-Surgical Immune Recovery

Accelerates immune system recovery following major surgery or chemotherapy through lymphocyte restoration.

Exercise-Induced Immunosuppression

Counters stress-induced immune suppression in athletes and high-stress situations.

Anti-Aging
Preliminary Data

Thymic Regeneration

Supports age-related thymic decline through hormone replacement therapy in elderly populations.

Immune Senescence Prevention

Delays age-related immune deterioration with improved vaccine responses.

Cellular Health
Preliminary Data

Antioxidant Enzyme Enhancement

Increases antioxidant enzyme activity providing cellular protection against oxidative damage.

Mitochondrial Function Support

Supports cellular energy metabolism and protects against age-related mitochondrial decline.

Research Protocols

As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.

This member section describes parameters reported in the research literature.

Sign in to view this section

Peptide Interactions

This member section summarizes reported compound interactions and evidence limitations.

Sign in to view this section

Reported Research Time Points

This member section summarizes reported research time points.

Sign in to view this section

Safety Notes

Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.

This member section discusses research safety considerations and uncertainties.

Sign in to view this section

Quality Indicators

Verified Marker

White Lyophilized Powder

Properly freeze-dried powder appears as white, fluffy powder that fills most of the vial bottom. Professional pharmaceutical packaging with sealed rubber stopper.

Verified Marker

Clear Solution After Reconstitution

When mixed with BAC water, solution should be crystal clear with no particles, cloudiness, or precipitation. Any turbidity indicates degradation.

Verified Marker

Proper Pharmaceutical Labeling

Vials should have clear labeling with batch numbers, expiration dates, and filling dosage (mg per vial) clearly marked. Unlabeled vials are a red flag.

Acceptable Range

Minor Powder Compaction

Slight compaction during shipping is acceptable — if powder dissolves completely and solution is clear with gentle swirling, the product is not degraded.

Quality Concern

Discolored or Collapsed Powder

Yellow, brown, or collapsed powder indicates degradation from heat exposure or moisture damage. Use is prohibited.

Quality Concern

Persistent Cloudiness

Solution remains cloudy, contains particles, or shows precipitation after reconstitution — indicates a degraded product. Discard immediately.

Research Citations

"

Research Focus

Immune enhancement, Viral infections, Cancer immunotherapy, T-cell activation, Hepatitis treatment

Verified Vendors Carrying Thymosin Alpha-1

Related Compounds

Related Articles

Browse all peptides in the Encyclopedia →